Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution

Iva Spreitzer, Josefin Keife, T. Strasser, Predrag Kalaba, Jana Lubec, Winfried Neuhaus, Gert Lübec, Thierry Langer, Judith Wackerlig, Irena LoryanInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This study compares the brain distribution and metabolism of a novel dopamine transporter inhibitor, S-CE-123, with the well-known cognitive enhancer R-modafinil. S-CE-123 shows significantly better blood-brain barrier (BBB) penetration and a more favorable distribution within brain tissue, making it a promising candidate for cognitive enhancement therapies.

What Problem Does This Paper Address?

Cognitive decline, associated with aging and neurodegenerative diseases, is a growing global health concern. Dopamine plays a crucial role in cognitive functions, and targeting the dopamine transporter (DAT) is a key strategy for developing cognitive enhancers. While modafinil is a known DAT inhibitor with wake-promoting and cognitive-enhancing effects, its use is associated with side effects and limitations. This paper addresses the need for more effective and safer cognitive enhancers by investigating a novel DAT inhibitor, S-CE-123, and comparing its pharmacokinetic and neuropharmacokinetic properties, particularly its central nervous system (CNS) distribution and metabolism, to R-modafinil. Understanding these properties is critical for predicting a drug's efficacy and potential side effects.

Methods

The researchers developed and partially validated a precise liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for quantifying S-CE-123 and R-modafinil in biological samples. They employed the Combinatory Mapping Approach (CMA), a high-throughput method that integrates in vivo and in vitro techniques to assess drug properties related to BBB transport and intra-brain distribution. Key techniques included:

  • In vivo rat pharmacokinetic (PK) studies: Measuring drug concentrations in blood, cerebrospinal fluid (CSF), and various tissues (brain, spinal cord, liver, kidneys) after a constant intravenous infusion to achieve steady-state conditions.
  • In vitro drug tissue binding assays: Using equilibrium dialysis to determine the unbound fraction of drugs in plasma (fu,plasma) and brain homogenate (fu,brain).
  • In vitro brain slice assay: Estimating the unbound volume of distribution in the brain (Vu,brain).
  • In vitro human liver microsome (HLM) assays: Assessing the metabolic stability of the compounds.

These methods allowed for the calculation of crucial neuropharmacokinetic (neuroPK) parameters, such as the unbound brain-to-plasma concentration ratio (Kp,uu,brain) and the unbound intracellular-to-extracellular concentration ratio (Kp,uu,cell).

Datasets

Not discussed in the paper. The study utilized Sprague-Dawley rats for in vivo experiments and human liver microsomes for in vitro metabolism studies.

Key Insights and Ideas

  • S-CE-123 is a superior BBB penetrator: The most striking finding is S-CE-123's significantly higher ability to cross the blood-brain barrier compared to R-modafinil, as evidenced by its much higher unbound brain-to-plasma concentration ratio (Kp,uu,brain). This is crucial for drugs targeting the CNS.
  • Differential brain tissue distribution: S-CE-123 appears to primarily reside in the brain's interstitial space, the fluid-filled area between cells, which is a desirable location for drug action. In contrast, R-modafinil distributes more evenly across the plasma membranes of brain cells.
  • Metabolic instability of S-CE-123: While S-CE-123 shows excellent BBB penetration, it is also metabolized much faster in the liver than R-modafinil. This suggests a potentially shorter half-life but also highlights the importance of understanding its metabolites.
  • R-modafinil's plasma instability: Interestingly, R-modafinil was found to be unstable in rat plasma, undergoing significant metabolism. This is an important consideration for designing PK/PD studies with R-modafinil.
  • Unexpected metabolite presence: Metabolites of both S-CE-123 and R-modafinil were detected in brain and spinal cord samples, which was unexpected and warrants further investigation into their potential CNS effects.

Key Results

  • Kp,uu,brain: S-CE-123 had a Kp,uu,brain of 0.46, significantly higher than R-modafinil's 0.097, indicating a 5-fold greater extent of BBB transport for S-CE-123.
  • Kp,uu,cell: S-CE-123 showed a Kp,uu,cell of 0.18, suggesting it primarily resides in the brain interstitial space, while R-modafinil's Kp,uu,cell of 0.85 indicates more even distribution across brain cell membranes.
  • Metabolic Stability: S-CE-123 exhibited a 9.3-fold faster metabolism in human liver microsomes compared to R-modafinil.
  • Plasma Stability: R-modafinil showed significant instability in rat plasma, with approximately 50% metabolized after 4 hours.

Limitations and Future Work

  • Metabolite roles: The study detected metabolites of both compounds in CNS tissues, but their specific roles in cognitive function or potential toxicity remain unclear. Further research is needed to elucidate these relationships.
  • Species differences: The study was conducted in rats. Future work should investigate whether these findings translate to other species, particularly humans, given potential differences in drug metabolism and transporter activity.
  • Long-term effects: While S-CE-123 shows promising acute distribution properties, its long-term efficacy, safety, and potential for tolerance require further investigation.
  • Clinical translation: The findings provide a strong foundation for further PKPD research and potential clinical trials of S-CE-123 as a cognitive enhancer.

Summary updated

Abstract

<i>S</i>-CE-123, a novel dopamine transporter inhibitor, has emerged as a potential candidate for cognitive enhancement. The objective of this study was to compare the tissue distribution profiles, with a specific focus on central nervous system distribution and metabolism, of <i>S</i>-CE-123 and <i>R</i>-modafinil. To address this objective, a precise liquid chromatography-high resolution mass spectrometry method was developed and partially validated. Neuropharmacokinetic parameters were assessed using the Combinatory Mapping Approach. Our findings reveal distinct differences between the two compounds. Notably, <i>S</i>-CE-123 demonstrates a significantly superior extent of transport across the blood-brain barrier (BBB), with an unbound brain-to-plasma concentration ratio (K<sub>p,uu,brain</sub>) of 0.5, compared to <i>R</i>-modafinil's K<sub>p,uu,brain</sub> of 0.1. A similar pattern was observed for the transport across the blood-spinal cord barrier. Concerning the drug transport across cellular membranes, we observed that <i>S</i>-CE-123 primarily localizes in the brain interstitial space, whereas <i>R</i>-modafinil distributes more evenly across both sides of the plasma membrane of the brain's parenchymal cells (K<sub>p,uu,cell</sub>). Furthermore, our study highlights the substantial differences in hepatic metabolic stability, with <i>S</i>-CE-123 having a 9.3-fold faster metabolism compared to <i>R</i>-modafinil. In summary, the combination of improved BBB transport and higher affinity of <i>S</i>-CE-123 to dopamine transporters in comparison to <i>R</i>-modafinil makes <i>S</i>-CE-123 a promising candidate for further testing for the treatment of cognitive decline.
BibTeX
@article{spreitzer2023pharmacokinetics,
  author = {Iva Spreitzer and Josefin Keife and T. Strasser and Predrag Kalaba and Jana Lubec and Winfried Neuhaus and Gert Lübec and Thierry Langer and Judith Wackerlig and Irena Loryan},
  title = {{Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242316956},
}
Figure